The incidence of grade 3-4 sepsis was similar at 16% with chemotherapy and 20% with gemtuzumab, as was the rate of ICU admission (12% vs. 14%).
Additional data at the meeting also show a significant survival benefit with gemtuzumab among 806 older patients, with a median age of 67 years, according to Dr. Alan Burnett, head of hematology at Cardiff (Wales) University. Median overall survival increased from 39% to 47% with the addition of gemtuzumab to chemotherapy (P = .02). A lower benefit was observed in those with adverse cytogenetics or secondary disease, according to the study.
Dr. Castaigne reported financial relationships with Pfizer/Wyeth. Dr. Burnett reported financial relationships with Pfizer. Dr. Tallman reported consulting for Genzyme Oncology.